Fig. 6From: High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myelomaSevere CRS resulted in HLH in Patient 6. A CAR+ cells in PBMC of Patient 6 was tested by FCM before and after BCMA-CD38 CAR-T infusion. Curves of max value of temperature (Tmax) and CRP before and after CAR-T infusion was recorded. B Curves of inflammatory factors (Ferritin, IL-6, and D2 polymer) of Patient 6 before and after BCMA-CD38 CAR-T infusion. C Morphology and FCM analysis detecting CD269 and CD38 staining of BMC of Patient 6 before, 1 and 2 months after BCMA-CD38 CAR-T infusion. D The extramedullary lesion images of Patient 6 before and 2 months after BCMA-CD38 CAR-T infusion. E White blood cells (WBC), hemoglobin (HGB) and platelet (PLT) levels of Patient 6 before and after BCMA-CD38 CAR-T infusionBack to article page